Reformulation Specialist Lipella Eyes $7m Injection From IPO
505(b)(2) Specialist Recently Lowered Expectations For Public Offering
Executive Summary
With a focus on developing novel drugs by reformulating the active agents in existing generics and optimizing these reformulations for new applications, Lipella is set to emerge as a public company.